Integra LifeSciences (IART)

Medical device company Integra LifeSciences (NASDAQ:IART) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 3.7% year on year to $382.7 million. On the other hand, next quarter’s revenue guidance of $395 million was less impressive, coming in 5.3% below analysts’ estimates. Its non-GAAP profit of $0.41 per share was 4.9% below analysts’ consensus estimates.

Company Overview

Founded in 1989 as a pioneer in regenerative medicine technology, Integra LifeSciences (NASDAQ:IART) develops and manufactures medical technologies for neurosurgery, wound care, and surgical reconstruction, including regenerative tissue products and surgical instruments.

The surgical equipment and consumables industry provides tools, devices, and disposable products essential for surgeries and medical procedures. These companies therefore benefit from relatively consistent demand, driven by the ongoing need for medical interventions, recurring revenue from consumables, and long-term contracts with hospitals and healthcare providers. However, the high costs of R&D and regulatory compliance, coupled with intense competition and pricing pressures from cost-conscious customers, can constrain profitability. Over the next few years, tailwinds include aging populations, which tend to need surgical interventions at higher rates. The increasing integration of AI and robotics into surgical procedures could also create opportunities for differentiation and innovation. However, the industry faces headwinds including potential supply chain vulnerabilities, evolving regulatory requirements, and more widespread efforts to make healthcare less costly.

Integra LifeSciences competes with several major medical technology companies, including Medtronic (NYSE:MDT), Stryker Corporation (NYSE:SYK), and Steris PLC (NYSE:STE) in its neurosurgical and surgical instrument markets. In the regenerative medicine and wound care segments, key competitors include Smith & Nephew (NYSE:SNN), Organogenesis (NASDAQ:ORGO), MiMedx Group (NASDAQ:MDXG), and Axogen (NASDAQ:AXGN).

Larger companies benefit from economies of scale, where fixed costs like infrastructure, technology, and administration are spread over a higher volume of goods or services, reducing the cost per unit. Scale can also lead to bargaining power with suppliers, greater brand recognition, and more investment firepower. A virtuous cycle can ensue if a scaled company plays its cards right.

With just $1.62 billion in revenue over the past 12 months, Integra LifeSciences is a small company in an industry where scale matters. This makes it difficult to build trust with customers because healthcare is heavily regulated, complex, and resource-intensive.

A company’s long-term sales performance can indicate its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Over the last five years, Integra LifeSciences grew its sales at a tepid 1.4% compounded annual growth rate. This fell short of our benchmarks and is a poor baseline for our analysis.

Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Integra LifeSciences’s annualized revenue growth of 2% over the last two years aligns with its five-year trend, suggesting its demand was consistently weak.

We can better understand the company’s sales dynamics by analyzing its organic revenue, which strips out one-time events like acquisitions and currency fluctuations that don’t accurately reflect its fundamentals. Over the last two years, Integra LifeSciences’s organic revenue averaged 1.6% year-on-year declines. Because this number is lower than its normal revenue growth, we can see that some mixture of acquisitions and foreign exchange rates boosted its headline results.

This quarter, Integra LifeSciences grew its revenue by 3.7% year on year, and its $382.7 million of revenue was in line with Wall Street’s estimates. Company management is currently guiding for a 5.5% year-on-year decline in sales next quarter.

Looking further ahead, sell-side analysts expect revenue to grow 4.5% over the next 12 months. Although this projection suggests its newer products and services will catalyze better top-line performance, it is still below the sector average.

Integra LifeSciences has managed its cost base well over the last five years. It demonstrated solid profitability for a healthcare business, producing an average operating margin of 15.2%.

Analyzing the trend in its profitability, Integra LifeSciences’s operating margin decreased by 9.3 percentage points over the last five years. This performance was caused by more recent speed bumps as the company’s margin fell by 11.1 percentage points on a two-year basis. We’re disappointed in these results because it shows its expenses were rising and it couldn’t pass those costs onto its customers.

In Q1, Integra LifeSciences generated an operating profit margin of negative 4%, down 15 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue.

Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions.

Sadly for Integra LifeSciences, its EPS declined by 1.2% annually over the last five years while its revenue grew by 1.4%. This tells us the company became less profitable on a per-share basis as it expanded due to non-fundamental factors such as interest expenses and taxes.

We can take a deeper look into Integra LifeSciences’s earnings to better understand the drivers of its performance. As we mentioned earlier, Integra LifeSciences’s operating margin declined by 9.3 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its lower earnings; taxes and interest expenses can also affect EPS but don’t tell us as much about a company’s fundamentals.

In Q1, Integra LifeSciences reported EPS at $0.41, down from $0.55 in the same quarter last year. This print missed analysts’ estimates. Over the next 12 months, Wall Street expects Integra LifeSciences’s full-year EPS of $2.42 to grow 7.2%.

Although earnings are undoubtedly valuable for assessing company performance, we believe cash is king because you can’t use accounting profits to pay the bills.

Integra LifeSciences has shown decent cash profitability, giving it some flexibility to reinvest or return capital to investors. The company’s free cash flow margin averaged 9.2% over the last five years, slightly better than the broader healthcare sector.

Taking a step back, we can see that Integra LifeSciences’s margin dropped by 17.1 percentage points during that time. If its declines continue, it could signal increasing investment needs and capital intensity.

Integra LifeSciences burned through $40.18 million of cash in Q1, equivalent to a negative 10.5% margin. The company’s cash burn increased meaningfully year on year and is a deviation from its longer-term margin, indicating it is a seasonal business that must build up inventory during certain quarters.

EPS and free cash flow tell us whether a company was profitable while growing its revenue. But was it capital-efficient? A company’s ROIC explains this by showing how much operating profit it makes compared to the money it has raised (debt and equity).

Integra LifeSciences historically did a mediocre job investing in profitable growth initiatives. Its five-year average ROIC was 6.7%, somewhat low compared to the best healthcare companies that consistently pump out 20%+.

We like to invest in businesses with high returns, but the trend in a company’s ROIC is what often surprises the market and moves the stock price. Over the last few years, Integra LifeSciences’s ROIC averaged 2.8 percentage point decreases each year. Paired with its already low returns, these declines suggest its profitable growth opportunities are few and far between.

Integra LifeSciences reported $273.3 million of cash and $1.84 billion of debt on its balance sheet in the most recent quarter. As investors in high-quality companies, we primarily focus on two things: 1) that a company’s debt level isn’t too high and 2) that its interest payments are not excessively burdening the business.

With $314 million of EBITDA over the last 12 months, we view Integra LifeSciences’s 5.0× net-debt-to-EBITDA ratio as safe. We also see its $27.61 million of annual interest expenses as appropriate. The company’s profits give it plenty of breathing room, allowing it to continue investing in growth initiatives.

It was good to see Integra LifeSciences narrowly top analysts’ organic revenue expectations this quarter. On the other hand, its full-year EPS guidance missed significantly and its revenue guidance for next quarter fell short of Wall Street’s estimates. Overall, this quarter could have been better. The stock traded down 1.6% to $16.55 immediately following the results.

Updated: May 22, 2025 at 11:47 PM EDT

Before investing in or passing on Integra LifeSciences, we urge you to understand the company’s business quality (or lack thereof), valuation, and the latest quarterly results - in that order.

We see the value of companies helping consumers, but in the case of Integra LifeSciences, we’re out. For starters, its revenue growth was uninspiring over the last five years. And while its sturdy operating margins show it has disciplined cost controls, the downside is its cash profitability fell over the last five years. On top of that, its declining EPS over the last five years makes it a less attractive asset to the public markets.

Integra LifeSciences’s P/E ratio based on the next 12 months is 4.9x. While this valuation is optically cheap, the potential downside is huge given its shaky fundamentals. There are better stocks to buy right now.

Wall Street analysts have a consensus one-year price target of $16.13 on the company (compared to the current share price of $12.72).

Although the price target is bullish, readers should exercise caution because analysts tend to be overly optimistic. The firms they work for, often big banks, have relationships with companies that extend into fundraising, M&A advisory, and other rewarding business lines. As a result, they typically hesitate to say bad things for fear they will lose out. We at StockStory do not suffer from such conflicts of interest, so we’ll always tell it like it is.

Want to invest in a High Quality big tech company? We’d point you in the direction of Microsoft and Google, which have durable competitive moats and strong fundamentals, factors that are large determinants of long-term market outperformance.

To get the best start with StockStory, check out our most recent stock picks, and then sign up for our earnings alerts by adding companies to your watchlist. We typically have quarterly earnings results analyzed within seconds of the data being released, giving investors the chance to react before the market has fully absorbed the information. This is especially true for companies reporting pre-market.